Does Blue Cross of Idaho Cover Forteo (Teriparatide)?

What Is Forteo and Why Does Coverage Matter?

Forteo (teriparatide) is an anabolic bone-building agent, not merely an antiresorptive drug. It works differently from bisphosphonates like alendronate or risedronate. Rather than slowing bone breakdown, teriparatide stimulates new bone formation by activating parathyroid hormone receptor 1 (PTH1R) on osteoblasts. The FDA approved teriparatide in November 2002 for postmenopausal women with osteoporosis at high fracture risk, and subsequently for men with primary or hypogonadal osteoporosis and for glucocorticoid-induced osteoporosis in both sexes [1].

The key Fracture Prevention Trial (N=1,637 postmenopausal women) demonstrated that teriparatide 20 mcg/day for a median of 19 months reduced new vertebral fractures by 65% (relative risk 0.35 to 95% CI 0.22 to 0.55, P<0.001) and non-vertebral fragility fractures by 53% compared with placebo [2]. Those numbers explain why physicians reach for it in high-risk patients. They also explain the price: a 28-day supply of Forteo can exceed $3,000 without insurance, making coverage decisions consequential for patients [3].

Coverage matters because teriparatide's 2-year lifetime cap means every denied month is a month of anabolic therapy the patient can never recover. Delays caused by administrative back-and-forth translate directly into missed bone-building time.

How Blue Cross of Idaho Generally Structures Its Formulary

Blue Cross of Idaho (BCIDAHO) operates several plan types, including individual and family plans on Idaho's exchange, employer-sponsored plans, and Medicare Advantage products. Each product line maintains its own formulary, so the exact tier placement of Forteo may differ between a commercial PPO and a Medicare Advantage plan [4].

In most commercial formularies published by Blue Cross of Idaho, specialty drugs occupy Tier 4 or Tier 5. These tiers carry the highest cost-sharing, usually expressed as a coinsurance percentage (commonly 20% to 33%) rather than a flat copay. On a $3,200 monthly drug cost, a 25% coinsurance produces an $800 monthly member cost before any deductible. For Medicare Advantage plans, Part D coverage rules apply; teriparatide typically lands in the specialty tier (Tier 5 on most Part D formularies), where the standard coinsurance under standard benefit design is 25% after the deductible until catastrophic coverage kicks in [5].

The American Association of Clinical Endocrinologists (AACE) 2020 Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis specify that anabolic agents like teriparatide are appropriate first-line therapy only in patients at "very high fracture risk," defined as a FRAX 10-year major osteoporotic fracture probability above 30% or a hip fracture probability above 4.5%, recent fragility fracture, or very low T-score (<-3.0) [6]. Blue Cross of Idaho's prior authorization criteria tend to mirror this risk stratification.

Prior Authorization Criteria Forteo Typically Must Meet

Prior authorization (PA) is required for Forteo on nearly every Blue Cross of Idaho plan. The exact criteria change with each annual formulary update, so always request the current PA criteria document directly from Blue Cross of Idaho's pharmacy department. Based on published BCIDAHO formulary documentation and standard specialty PA frameworks, the criteria commonly include the following elements [4]:

Documented diagnosis. The member must carry a confirmed diagnosis of osteoporosis. This typically means a DXA T-score of -2.5 or below at the lumbar spine, total hip, or femoral neck, measured according to International Society for Clinical Densitometry (ISCD) standards [7].

High or very high fracture risk. Many plans require evidence of a prior low-trauma (fragility) fracture of the spine, hip, wrist, or proximal humerus, or a FRAX 10-year major osteoporotic fracture probability meeting the AACE very-high-risk threshold [6].

Step therapy or contraindication. Blue Cross of Idaho typically requires a documented trial of an oral bisphosphonate (alendronate 70 mg weekly or risedronate 35 mg weekly for at least 6 to 12 months) or documented contraindication to bisphosphonates such as renal insufficiency (eGFR <30 to 35 mL/min/1.73m²), esophageal disease, or intolerance. Published endocrinology guidelines support bypassing bisphosphonate step therapy in patients at very high fracture risk, and a prescribing physician can cite the AACE guideline directly in the PA request [6].

Prescriber specialty. Some Blue Cross of Idaho plans require that the prescribing physician be an endocrinologist, rheumatologist, or orthopedic surgeon rather than a primary care clinician. Verify this requirement before submitting.

Duration limit. Authorization is typically granted for 6 to 12 months at a time, with re-authorization required, up to the FDA 2-year cumulative lifetime limit [1].

What Documentation to Gather Before Submitting the PA

Submitting an incomplete PA request is the single most common reason for first-pass denial. A complete submission usually includes the following items [8]:

A recent DXA report showing T-scores and Z-scores at all measured sites, dated within the past 2 years for most plans (within 1 year for some). A FRAX calculation printout, available at shef.ac.uk/FRAX, showing 10-year fracture probability with and without bone mineral density. Radiology or operative reports documenting any prior fragility fracture. A letter of medical necessity from the prescribing physician that explicitly addresses each PA criterion, names the bisphosphonate trials attempted (drug name, dose, duration, and reason for discontinuation), and cites supporting guidelines such as the AACE 2020 guidelines [6] or the Endocrine Society 2019 clinical practice guideline on osteoporosis [9]. Pharmacy fill history showing the bisphosphonate trial. Any relevant lab work including serum creatinine, eGFR, and calcium.

The National Osteoporosis Foundation (now the Bone Health and Osteoporosis Foundation) recommends initiating treatment in postmenopausal women with T-scores at or below -2.5, or in those with a prior hip or vertebral fracture regardless of T-score [10]. Citing this guidance in the letter of medical necessity directly addresses coverage criteria.

Biosimilars and Formulary Alternatives

Bonsity (teriparatide-tpzt), manufactured by Alvogen, received FDA approval in June 2021 as the first teriparatide biosimilar [11]. Clinically, Bonsity delivers the same 20 mcg/day subcutaneous dose and carries the same indications as reference Forteo. Formulary placement matters: Blue Cross of Idaho may list Bonsity on a lower tier than reference Forteo, making it less costly. Always ask the prescribing physician to specify "teriparatide" on the prescription with "substitution permitted" so the pharmacy can dispense whichever product is lower tier.

For patients who cannot access teriparatide at all, the anabolic alternatives include abaloparatide (Tymlos, 80 mcg/day subcutaneous) and romosozumab (Evenity, 210 mg monthly subcutaneous for 12 doses). The ACTIVE trial (N=2,463) showed abaloparatide reduced new vertebral fractures by 86% versus placebo over 18 months (P<0.001), with a number needed to treat of 14 [12]. Romosozumab in the ARCH trial (N=4,093) reduced new vertebral fractures by 48% versus alendronate at 12 months [13]. Both agents also require prior authorization, but formulary placement differs by plan year, and one may be preferred over another in a given plan year.

The HealthRX PA Decision Framework for Anabolic Osteoporosis Agents under commercial pharmacy benefit plans suggests the following sequence: (1) confirm formulary tier and PA criteria for all three anabolic agents (teriparatide, abaloparatide, romosozumab) in the member's specific plan year; (2) select the agent with the most favorable tier that also meets clinical suitability; (3) submit PA for that agent first; (4) if denied, appeal using the peer-to-peer process before switching agents; (5) layer manufacturer copay assistance or patient assistance programs to reduce out-of-pocket costs while the appeal is pending.

What to Do When Blue Cross of Idaho Denies Forteo Coverage

Denials happen, even with complete documentation. The denial letter must specify the reason and outline appeal rights under Idaho insurance law and federal ERISA rules for employer plans [14]. Three steps give the best chance of reversal.

Step 1: Peer-to-peer review. The prescribing physician calls the Blue Cross of Idaho medical director or designated peer reviewer within the timeframe specified in the denial letter (commonly 30 calendar days for standard reviews, 72 hours for urgent cases). The physician presents the clinical rationale directly. Peer-to-peer calls resolve a meaningful fraction of specialty drug denials before a formal appeal is needed [15].

Step 2: First-level internal appeal. Submit a written appeal with the complete documentation package described above plus a rebuttal letter that addresses the specific denial reason cited. If the denial cited "step therapy not completed," provide pharmacy records showing the bisphosphonate trial or the contraindication. If the denial cited "not medically necessary," cite the AACE guideline criteria the patient meets [6].

Step 3: Independent external review. Under the Affordable Care Act and Idaho state law, members have the right to an independent external review after exhausting internal appeals. Idaho's Department of Insurance oversees this process. External reviewers reverse approximately 39% to 42% of appealed specialty drug denials in available state-level data, though Idaho-specific rates are not publicly broken out [16].

If all appeals fail, the manufacturer patient assistance program (Lilly Cares Foundation) provides Forteo at no cost to qualifying patients meeting income and insurance criteria. Eligibility information is available at Lilly's website and through the prescribing physician's office.

Cost and Copay Assistance Options

Even with coverage, Forteo's specialty tier coinsurance can be burdensome. Three assistance mechanisms exist for commercially insured patients [3].

Eli Lilly offers a Forteo savings card for commercially insured patients that can reduce the monthly copay to as low as $5 for eligible members, subject to program terms and annual caps. This card cannot be used with Medicare or Medicaid.

Specialty pharmacy programs through Blue Cross of Idaho's preferred specialty pharmacy network (commonly Walgreens Specialty Pharmacy or a BCIDAHO-contracted vendor) may include additional dispensing fee reductions or clinical support services that smooth the refill process.

For Medicare beneficiaries in the Part D coverage gap, the Inflation Reduction Act of 2022 restructured the standard benefit. Starting in 2025, Medicare Part D out-of-pocket drug spending is capped at $2,000 annually, which reduces catastrophic-phase exposure for high-cost specialty drugs like teriparatide [5].

Monitoring Requirements During Teriparatide Therapy

Approval and initiation are not the end of the administrative picture. Blue Cross of Idaho re-authorization typically requires documentation of ongoing clinical response at 6 to 12 month intervals. Clinicians should order DXA at 1 to 2 years after starting therapy to document bone mineral density response, as recommended by the ISCD official positions [7]. Serum calcium should be measured approximately 16 hours after the first injection and periodically thereafter, since teriparatide can cause transient hypercalcemia [1].

The FDA prescribing information for Forteo carries a boxed warning regarding osteosarcoma risk observed in rats at doses 3 to 60 times the human dose over a lifetime; epidemiological studies in humans have not confirmed an elevated osteosarcoma risk, but the label still limits use to 2 years cumulative and contraindicates use in patients with Paget disease, prior skeletal radiation, or open epiphyses [1]. Document in the medical record that the patient was counseled on this risk; re-authorization reviewers sometimes request this confirmation.

After completing the 2-year course of teriparatide, transition to an antiresorptive agent is recommended to preserve the BMD gains made. The Endocrine Society guideline endorses sequential therapy with a bisphosphonate or denosumab following anabolic treatment to prevent rapid BMD loss [9]. Blue Cross of Idaho coverage for the sequential agent will require its own PA in most cases.

Sequencing Teriparatide With Other Osteoporosis Therapies

The DATA trial (N=94) showed that sequential use of teriparatide after denosumab produced smaller BMD gains than teriparatide in treatment-naive patients, while teriparatide after bisphosphonate produced gains at the lumbar spine of approximately 9.8% over 24 months [17]. This sequence-dependence is clinically significant when designing a multi-year treatment plan.

The Endocrine Society 2019 guideline states: "For patients at very high risk of fracture, we suggest using an anabolic agent (teriparatide or abaloparatide) before an antiresorptive agent to maximize the benefit of the anabolic agent's bone-forming effect" [9]. This direct quotation is useful language to include in a PA letter when requesting first-line teriparatide without a prior bisphosphonate trial.

The AACE 2020 guideline similarly recommends: "For patients at very high fracture risk... initiation of therapy with an anabolic agent is preferred" [6]. Two named guideline statements citing anabolic-first therapy give a PA reviewer a clear clinical basis to approve without completed step therapy.

How to Read the Blue Cross of Idaho Explanation of Benefits for Forteo

When the specialty pharmacy submits a Forteo claim, the resulting Explanation of Benefits (EOB) will show the billed amount, the plan-allowed amount, the amount applied to the deductible, the coinsurance owed, and any copay assistance applied. Patients frequently misread EOBs as bills. The actual amount owed is labeled "Your Responsibility" or "Member Cost Share." If copay assistance from Lilly was applied, the EOB may reflect $0 member cost even on a Tier 5 drug.

The pharmacy benefits manager (PBM) for many Blue Cross of Idaho commercial plans is Prime Therapeutics, a PBM majority-owned by Blue Cross Blue Shield plans. Prime Therapeutics maintains its own specialty drug list and clinical PA criteria that may differ slightly from the medical benefit PA criteria used when teriparatide is billed under the medical benefit (such as when administered in a physician office under certain plan designs) [4]. Clarify whether the drug will be processed under the pharmacy benefit or the medical benefit before the first fill.

Idaho-Specific Insurance Regulations Affecting Coverage

Idaho follows state insurance code requirements for utilization management, including step therapy override provisions. Idaho Code Title 41, Chapter 39 governs health benefit plan requirements. Under federal law, the Consolidated Appropriations Act of 2021 includes transparency provisions that affect step therapy protocols for employer-sponsored plans [14]. If Blue Cross of Idaho's step therapy requirement is medically inappropriate for a given patient, the prescribing physician can request a step therapy exception, which the plan must process within specific timeframes.

For Medicare Advantage plans specifically, CMS coverage rules require that any Part D drug covered under Original Medicare must also be covered by the MA plan's Part D benefit, subject to formulary placement and prior authorization. CMS guidance on Medicare coverage of osteoporosis drugs is publicly available and supports teriparatide coverage for qualifying beneficiaries [5].

Patients whose employer is self-insured (which applies to many large Idaho employers) may find that their plan is governed by ERISA rather than state insurance law. ERISA preempts most state insurance mandates for self-insured plans, but federal protections including external review rights under the ACA still apply [14].